- Home
- KALU vs GYRE Comparison
KALU vs GYRE Comparison
Compare KALU & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALU
- GYRE
- Stock Information
- Founded
- KALU 1946
- GYRE 2002
- Country
- KALU United States
- GYRE United States
- Employees
- KALU N/A
- GYRE N/A
- Industry
- KALU Metal Fabrications
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- KALU Industrials
- GYRE Health Care
- Exchange
- KALU Nasdaq
- GYRE Nasdaq
- Market Cap
- KALU 962.6M
- GYRE 897.1M
- IPO Year
- KALU 1991
- GYRE N/A
- Fundamental
- Price
- KALU $70.97
- GYRE $10.39
- Analyst Decision
- KALU Buy
- GYRE
- Analyst Count
- KALU 3
- GYRE 0
- Target Price
- KALU $69.00
- GYRE N/A
- AVG Volume (30 Days)
- KALU 191.3K
- GYRE 112.1K
- Earning Date
- KALU 04-23-2025
- GYRE 05-09-2025
- Dividend Yield
- KALU 4.31%
- GYRE N/A
- EPS Growth
- KALU 0.39
- GYRE N/A
- EPS
- KALU 3.06
- GYRE 0.02
- Revenue
- KALU $3,063,900,000.00
- GYRE $100,643,000.00
- Revenue This Year
- KALU $11.04
- GYRE $22.01
- Revenue Next Year
- KALU $7.33
- GYRE $88.14
- P/E Ratio
- KALU $23.34
- GYRE $127.70
- Revenue Growth
- KALU 1.56
- GYRE N/A
- 52 Week Low
- KALU $46.81
- GYRE $6.11
- 52 Week High
- KALU $102.42
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- KALU 65.53
- GYRE 57.93
- Support Level
- KALU $66.59
- GYRE $8.51
- Resistance Level
- KALU $72.78
- GYRE $11.78
- Average True Range (ATR)
- KALU 2.65
- GYRE 0.74
- MACD
- KALU 0.91
- GYRE 0.23
- Stochastic Oscillator
- KALU 88.05
- GYRE 58.75
About KALU Kaiser Aluminum Corporation
Kaiser Aluminum Corp produces and sells semi-fabricated specialty aluminum products predominantly to industrial customers. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from the United States.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.